| pubmed-article:2938955 | pubmed:abstractText | In the therapeutic schemes of the hormone-dependent gynecologic cancers, the combined administration of tamoxifen and medroxyprogesterone, generally, scores better results. The highly hormone-dependent tumors (ER+, PgR+) respond very well to a combined, simultaneous treatment. The strictly hormone-dependent (ER+, PgR-) and the potentially hormone-dependent (ER-, PgR-) tumors seem to be most efficiently treated by means of a combined, successive scheme. | lld:pubmed |
